Longeveron Inc. - Class A Common stock (LGVN)
LGVN moved a median of -0.01% 30 minutes after news, and -1.19% by the close. How LGVN actually reacts to news — the realized, point-in-time move the market made, measured across 405 labeled events over the last three years with zero look-ahead.
LGVN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 399 |
| 30-min | -0.01% | 44% | 403 |
| 60-min | -0.47% | 44% | 405 |
| to close | -1.19% | 36% | 403 |
| Middle 50% of LGVN reactions | -2.13% to +1.51% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 405 |
Half of all Longeveron Inc. - Class A Common stock news events land between -2.13% and +1.51% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LGVN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LGVN's baseline. Nothing else.
Recent LGVN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Longeveron Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | -10.71% | |
| Longeveron to Participate in Three Longevity/Aging Investment Conferences | Press release | GlobeNewswire | +0.00% | -4.78% | |
| Form 8-K Longeveron Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +14.57% | |
| Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) | Press release | GlobeNewswire | -1.27% | -13.69% | |
| Form 8-K Longeveron Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.43% | |
| Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +3.22% | -3.52% | |
| Form 8-K Longeveron Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +2.52% | |
| Form 8-K Longeveron Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -5.47% | -6.85% | |
| Longeveron Announces 1-for-10 Reverse Stock Split | Press release | GlobeNewswire | -5.47% | -6.85% | |
| Form 8-K Longeveron Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +2.14% | -1.41% | |
| Longeveron Appoints Nirav Jhaveri as Chief Financial Officer | Press release | GlobeNewswire | +2.14% | -1.41% | |
| Form 10-Q Longeveron Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.48% | +4.10% | |
| Form 8-K Longeveron Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | +4.10% | |
| Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.48% | +4.10% | |
| Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition | Press release | GlobeNewswire | +3.65% | -6.47% | |
| Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 | Press release | GlobeNewswire | +0.00% | -1.05% | |
| Form 8-K Longeveron Inc. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +13.50% | |
| Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors | Press release | GlobeNewswire | +1.01% | -4.18% | |
| Form 8-K Longeveron Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +1.18% | |
| Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease | Press release | GlobeNewswire | +1.94% | -8.04% | |
| Form S-8 Longeveron Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.94% | -8.04% | |
| Form 8-K Longeveron Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | +0.08% | |
| Form 8-K Longeveron Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -2.74% | |
| Longeveron® Appoints Marie Washburn as Chief Financial Officer | Press release | GlobeNewswire | -0.06% | -2.74% | |
| New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) | Press release | GlobeNewswire | +0.13% | -2.37% | |
| Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) | Press release | GlobeNewswire | +1.23% | +2.89% | |
| Form 8-K Longeveron Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +2.88% | |
| Longeveron to Present at BIO International Convention 2026 | Press release | GlobeNewswire | +2.47% | +1.27% | |
| Form ARS Longeveron Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.27% | -0.25% | |
| Form DEF 14A Longeveron Inc. For: Jul 01 | SEC filing · Form DEF | SEC EDGAR | -2.27% | -0.25% | |
| Form DEFA14A Longeveron Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.27% | -0.25% | |
| Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities | Press release | GlobeNewswire | -2.27% | -0.25% | |
| Form 10-Q Longeveron Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.40% | -6.94% | |
| Form 8-K Longeveron Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -6.94% | |
| Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.40% | -6.94% | |
| Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) | Press release | GlobeNewswire | +1.83% | +2.18% | |
| Form 8-K Longeveron Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | +2.18% | |
| Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | Press release | GlobeNewswire | +1.83% | +2.18% | |
| Form PRE 14A Longeveron Inc. For: May 05 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +1.63% | |
| Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 | Press release | GlobeNewswire | +0.00% | +1.63% | |
| Form EFFECT Longeveron Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -5.46% | |
| Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells | Press release | Canada Newswire | -0.43% | +0.87% | |
| Form 8-K Longeveron Inc. For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +0.00% | |
| Form S-1 Longeveron Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.89% | +0.00% | |
| Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | Press release | GlobeNewswire | -1.51% | -5.04% | |
| Form 8-K Longeveron Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | +1.29% | |
| Form D Longeveron Inc. | SEC filing · Form D | SEC EDGAR | +0.56% | +9.46% | |
| Form 8-K Longeveron Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +2.24% | +9.34% | |
| A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. | Press release | PR Newswire | +0.52% | +9.62% | |
| Form 10-K Longeveron Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.20% | +18.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LGVN section they belong to.
Where else LGVN is measured.
LGVN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Longeveron Inc. - Class A Common stock's median reaction calculated?
Every labeled LGVN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 405 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of LGVN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LGVN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.